黑色素瘤-话题@MedSci

#黑色素瘤#

32篇内容 | 7141人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1234208, encodeId=ba32123420845, content=<a href='/topic/show?id=ecc910668e7' target=_blank style='color:#2F92EE;'>#LAG3#</a><a href='/topic/show?id=330410333110' target=_blank style='color:#2F92EE;'>#黑色素瘤#</a>, objectTitle=NEJM：第三代免疫检查点上场：LAG-3+PD-1，晚期癌症无进展生存期提高一倍, objectType=article, longId=293793, objectId=02ce293e9390, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2022110/1641813669295_5295905.jpg, objectUrl=/article/show_article.do?id=02ce293e9390, replyNumber=0, likeNumber=130, createdTime=2022-07-23, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02ce293e9390, moduleTitle=NEJM：第三代免疫检查点上场：LAG-3+PD-1，晚期癌症无进展生存期提高一倍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02ce293e9390)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1234207, encodeId=a38c123420e28, content=<a href='/topic/show?id=ecc910668e7' target=_blank style='color:#2F92EE;'>#LAG3#</a><a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a><a href='/topic/show?id=330410333110' target=_blank style='color:#2F92EE;'>#黑色素瘤#</a>, objectTitle=FDA批准LAG-3抗体Relatlimab联合Nivolumab用于不可切除或转移性黑色素瘤的儿童和成人患者, objectType=article, longId=301197, objectId=1dfe30119ee0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20220316/1779a5a6c1344c8d9a3c460c24312058.jpg, objectUrl=/article/show_article.do?id=1dfe30119ee0, replyNumber=0, likeNumber=149, createdTime=2022-07-23, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1dfe30119ee0, moduleTitle=FDA批准LAG-3抗体Relatlimab联合Nivolumab用于不可切除或转移性黑色素瘤的儿童和成人患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1dfe30119ee0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1204292, encodeId=8dfb12042921f, content=<a href='/topic/show?id=330410333110' target=_blank style='color:#2F92EE;'>#黑色素瘤#</a><a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治疗#</a>, objectTitle=FDA批准LAG-3抗体Relatlimab联合Nivolumab用于不可切除或转移性黑色素瘤的儿童和成人患者, objectType=article, longId=301197, objectId=1dfe30119ee0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20220316/1779a5a6c1344c8d9a3c460c24312058.jpg, objectUrl=/article/show_article.do?id=1dfe30119ee0, replyNumber=0, likeNumber=175, createdTime=2022-03-20, rootId=0, userName=医者仁者, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1dfe30119ee0, moduleTitle=FDA批准LAG-3抗体Relatlimab联合Nivolumab用于不可切除或转移性黑色素瘤的儿童和成人患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1dfe30119ee0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1201262, encodeId=426c12012629b, content=<a href='/topic/show?id=4e9ae7349f2' target=_blank style='color:#2F92EE;'>#纳武单抗#</a>对<a href='/topic/show?id=330410333110' target=_blank style='color:#2F92EE;'>#黑色素瘤#</a>，瑞拉利单抗和纳武单抗组合，获益更大, objectTitle=NEJM：未经治疗晚期黑色素瘤患者该采用瑞拉利单抗-纳武单抗组合治疗还是单独纳武单抗治疗？, objectType=article, longId=293533, objectId=069e293533fd, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202216/1641456275898_1739456.jpg, objectUrl=/article/show_article.do?id=069e293533fd, replyNumber=0, likeNumber=176, createdTime=2022-03-10, rootId=0, userName=医者仁者, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=069e293533fd, moduleTitle=NEJM：未经治疗晚期黑色素瘤患者该采用瑞拉利单抗-纳武单抗组合治疗还是单独纳武单抗治疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=069e293533fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=973220, encodeId=78d19e32209d, content=体力活动、握力和久坐行为与恶性<a href='/topic/show?id=330410333110' target=_blank style='color:#2F92EE;'>#黑色素瘤#</a>风险无关，其实主要与晒太阳有关吧。, objectTitle=Brit J Cancer：运动、握力和久坐行为与恶性黑色素瘤发病率之间的关系, objectType=article, longId=212142, objectId=c2e121214201, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202161/1622506471836_1739456.png, objectUrl=/article/show_article.do?id=c2e121214201, replyNumber=0, likeNumber=186, createdTime=2021-06-13, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2e121214201, moduleTitle=Brit J Cancer：运动、握力和久坐行为与恶性黑色素瘤发病率之间的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2e121214201)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=916394, encodeId=59b591639494, content=<a href='/topic/show?id=330410333110' target=_blank style='color:#2F92EE;'>#黑色素瘤#</a>, objectTitle=J Immunother Cancer：采用免疫检查点抑制剂治疗的黑色素瘤患者静脉血栓栓塞的发生率, objectType=article, longId=205720, objectId=6c70205e20be, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021111/1610332177454_5295902.jpg, objectUrl=/article/show_article.do?id=6c70205e20be, replyNumber=0, likeNumber=216, createdTime=2021-01-14, rootId=0, userName=zb1235672, userId=59321624668, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c70205e20be, moduleTitle=J Immunother Cancer：采用免疫检查点抑制剂治疗的黑色素瘤患者静脉血栓栓塞的发生率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c70205e20be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=916382, encodeId=f20a91638273, content=<a href='/topic/show?id=330410333110' target=_blank style='color:#2F92EE;'>#黑色素瘤#</a>, objectTitle=J Immunother Cancer：采用免疫检查点抑制剂治疗的黑色素瘤患者静脉血栓栓塞的发生率, objectType=article, longId=205720, objectId=6c70205e20be, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021111/1610332177454_5295902.jpg, objectUrl=/article/show_article.do?id=6c70205e20be, replyNumber=0, likeNumber=194, createdTime=2021-01-13, rootId=0, userName=Nebula-Qin, userId=74c72110107, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c70205e20be, moduleTitle=J Immunother Cancer：采用免疫检查点抑制剂治疗的黑色素瘤患者静脉血栓栓塞的发生率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c70205e20be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=887715, encodeId=953d88e71578, content=<a href='/topic/show?id=330410333110' target=_blank style='color:#2F92EE;'>#黑色素瘤#</a><a href='/topic/show?id=597725653fd' target=_blank style='color:#2F92EE;'>#伊匹单抗#</a><a href='/topic/show?id=4e9ae7349f2' target=_blank style='color:#2F92EE;'>#纳武单抗#</a>联合可能更好, objectTitle=Lancet oncol：纳武单抗 vs 伊匹单抗作为高危黑色素瘤术后辅助治疗的4年随访结果！, objectType=article, longId=201125, objectId=c5a52011256e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020923/1600850266428_2110107.PNG, objectUrl=/article/show_article.do?id=c5a52011256e, replyNumber=0, likeNumber=288, createdTime=2020-09-23, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5a52011256e, moduleTitle=Lancet oncol：纳武单抗 vs 伊匹单抗作为高危黑色素瘤术后辅助治疗的4年随访结果！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5a52011256e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=887355, encodeId=582b88e35559, content=<a href='/topic/show?id=330410333110' target=_blank style='color:#2F92EE;'>#黑色素瘤#</a><a href='/topic/show?id=333a6802212' target=_blank style='color:#2F92EE;'>#特瑞普利单抗#</a>, objectTitle=PD1+溶瘤病毒，奥源和力公布OrienX010一项黑色素瘤Ib期研究结果, objectType=article, longId=201030, objectId=51052010304a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020921/1600696334951_52959052, objectUrl=/article/show_article.do?id=51052010304a, replyNumber=0, likeNumber=254, createdTime=2020-09-22, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51052010304a, moduleTitle=PD1+溶瘤病毒，奥源和力公布OrienX010一项黑色素瘤Ib期研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51052010304a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=885952, encodeId=6f9488595205, content=<a href='/topic/show?id=ee7b800133e' target=_blank style='color:#2F92EE;'>#羟氯喹#</a>联合MEK抑制剂用于<a href='/topic/show?id=330410333110' target=_blank style='color:#2F92EE;'>#黑色素瘤#</a>，毒性是否也会叠加？, objectTitle=Clin Cancer Res：抗疟疾药氯喹可增加GNAQ/11突变性黑色素瘤对MEK1/2抑制剂的敏感性！, objectType=article, longId=200796, objectId=d03f200e96fe, topicUrl=null, isHasObj=0, objectCover=, objectUrl=/article/show_article.do?id=d03f200e96fe, replyNumber=0, likeNumber=336, createdTime=2020-09-17, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d03f200e96fe, moduleTitle=Clin Cancer Res：抗疟疾药氯喹可增加GNAQ/11突变性黑色素瘤对MEK1/2抑制剂的敏感性！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d03f200e96fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=882568, encodeId=4e62882568b7, content=<a href='/topic/show?id=330410333110' target=_blank style='color:#2F92EE;'>#黑色素瘤#</a>很可怕，Dabrafenib联合Trametinib 治疗可降低黑色素瘤患者复发或远端转移风险。这是个好消息。, objectTitle=NEJM：Dabrafenib联合Trametinib 治疗III期黑色素瘤患者长期生存数据喜人, objectType=article, longId=200218, objectId=b6bb200218dc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202093/1599129982123_2051781.jpg, objectUrl=/article/show_article.do?id=b6bb200218dc, replyNumber=0, likeNumber=217, createdTime=2020-09-03, rootId=0, userName=Jessica, userId=3a345397082, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6bb200218dc, moduleTitle=NEJM：Dabrafenib联合Trametinib 治疗III期黑色素瘤患者长期生存数据喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6bb200218dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=882447, encodeId=ba3488244e67, content=<a href='/topic/show?id=330410333110' target=_blank style='color:#2F92EE;'>#黑色素瘤#</a>的<a href='/topic/show?id=afa5965438d' target=_blank style='color:#2F92EE;'>#铁死亡#</a>过于基础了，不一定有临床价值, objectTitle=Nature: 推波助澜，淋巴系统可保护瘤细胞免于铁死亡，促进癌细胞转移, objectType=article, longId=200200, objectId=903d200200ae, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20200828/3250da74a6144686983b6abe89fc1ab4.jpg, objectUrl=/article/show_article.do?id=903d200200ae, replyNumber=0, likeNumber=261, createdTime=2020-09-03, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=903d200200ae, moduleTitle=Nature: 推波助澜，淋巴系统可保护瘤细胞免于铁死亡，促进癌细胞转移, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=903d200200ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

黑色素瘤

2020-05-29发表于威斯康星

病毒猎手

#LAG3##黑色素瘤#

NEJM：第三代免疫检查点上场：LAG-3+PD-1，晚期癌症无进展生存期提高一倍

2022-07-23

病毒猎手

#LAG3##肿瘤##黑色素瘤#

FDA批准LAG-3抗体Relatlimab联合Nivolumab用于不可切除或转移性黑色素瘤的儿童和成人患者

2022-07-23

医者仁者

#黑色素瘤##免疫治疗#

FDA批准LAG-3抗体Relatlimab联合Nivolumab用于不可切除或转移性黑色素瘤的儿童和成人患者

2022-03-20

医者仁者

#纳武单抗#对#黑色素瘤#，瑞拉利单抗和纳武单抗组合，获益更大

NEJM：未经治疗晚期黑色素瘤患者该采用瑞拉利单抗-纳武单抗组合治疗还是单独纳武单抗治疗？

2022-03-10

病毒猎手

体力活动、握力和久坐行为与恶性#黑色素瘤#风险无关，其实主要与晒太阳有关吧。

Brit J Cancer：运动、握力和久坐行为与恶性黑色素瘤发病率之间的关系

2021-06-13

zb1235672

#黑色素瘤#

J Immunother Cancer：采用免疫检查点抑制剂治疗的黑色素瘤患者静脉血栓栓塞的发生率

2021-01-14

Nebula-Qin

#黑色素瘤#

J Immunother Cancer：采用免疫检查点抑制剂治疗的黑色素瘤患者静脉血栓栓塞的发生率

2021-01-13

lovetcm

#黑色素瘤##伊匹单抗##纳武单抗#联合可能更好

Lancet oncol：纳武单抗 vs 伊匹单抗作为高危黑色素瘤术后辅助治疗的4年随访结果！

2020-09-23

lovetcm

#黑色素瘤##特瑞普利单抗#

PD1+溶瘤病毒，奥源和力公布OrienX010一项黑色素瘤Ib期研究结果

2020-09-22

lovetcm

#羟氯喹#联合MEK抑制剂用于#黑色素瘤#，毒性是否也会叠加？

Clin Cancer Res：抗疟疾药氯喹可增加GNAQ/11突变性黑色素瘤对MEK1/2抑制剂的敏感性！

2020-09-17

Jessica

#黑色素瘤#很可怕，Dabrafenib联合Trametinib 治疗可降低黑色素瘤患者复发或远端转移风险。这是个好消息。

NEJM：Dabrafenib联合Trametinib 治疗III期黑色素瘤患者长期生存数据喜人

2020-09-03

lovetcm

#黑色素瘤#的#铁死亡#过于基础了，不一定有临床价值

Nature: 推波助澜，淋巴系统可保护瘤细胞免于铁死亡，促进癌细胞转移

2020-09-03

科室
- - 订阅+
  - 更多科室
工具
服务